Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China

doi:10.1111/1759-7714.14274

	Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China
	Shi, Yuequan 4; Fang, Jian 3; Zhou, Chengzhi 2; Liu, Anwen 20; Wang, Yan 1; Meng, Qingwei 19; Ding, Cuimin 18; Ai, Bin 17; Gu, Yangchun 16; Yao, Yu 15
刊名	THORACIC CANCER
	2021-12-21
关键词	advanced lung cancer immune checkpoint inhibitors immune-related adverse events real-world data
ISSN号	1759-7706
DOI	10.1111/1759-7714.14274
通讯作者	Wang, Mengzhao(mengzhaowang@sina.com)
英文摘要	Background Immune checkpoint inhibitors (ICIs) are the standard treatment for advanced lung cancer, but immune-related adverse events (irAEs) remain poorly understood, especially in a real-world setting. Methods A multicenter observational study was conducted. Medical records of lung cancer patients treated with ICIs at 26 hospitals from January 1, 2015, to February 28, 2021, were retrieved. Types of ICIs included antiprogrammed cell death 1 or antiprogrammed cell death ligand 1 (PD-L1) monotherapy, anticytotoxic T-lymphocyte antigen-4 monotherapy, or combination therapy. Results In total, 1905 patients with advanced lung cancer were evaluated. The median age was 63 (range 28-87) years, and the male/female ratio was 3.1:1 (1442/463). The primary histological subtype was adenocarcinoma (915). A total of 26.9% (512/1905) of the patients developed 671 irAEs, and 5.8% (110/1905) developed 120 grade 3-5 irAEs. Median duration from ICI initiation to irAEs onset was 56 (range 0-1160) days. The most common irAEs were thyroid dysfunction (7.2%, 138/1905), pneumonitis (6.5%, 124/1905), and dermatological toxicities (6.0%, 115/1905). A total of 162 irAEs were treated with steroids and 11 irAEs led to death. Patients with positive PD-L1 expression (>= 1%) and who received first-line ICI treatment developed more irAEs. Patients who developed irAEs had a better disease control rate (DCR, 71.3% [365/512] vs. 56.0% [780/1145]; p < 0.001). Conclusions The incidence rate of irAEs was 26.9% in a real-world setting. IrAEs might be related to a better DCR, but clinicians should be more aware of irAE recognition and management in clinical practice.
资助项目	Merk Co., Ltd.
WOS关键词	EFFICACY ; PEMBROLIZUMAB ; IMMUNOTHERAPY ; CHEMOTHERAPY ; NIVOLUMAB ; OUTCOMES
WOS研究方向	Oncology ; Respiratory System
语种	英语
出版者	WILEY
WOS记录号	WOS:000732478600001
资助机构	Merk Co., Ltd.
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/126988]
专题	中国科学院合肥物质科学研究院
通讯作者	Wang, Mengzhao
作者单位	1.Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Dept Med Oncol,Natl Canc Ctr, Beijing, Peoples R China 2.Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Inst Resp Hlth, State Key Lab Resp Dis,Natl Clin Res Ctr Resp Dis, Guangzhou, Peoples R China 3.Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Dept Thorac Oncol 2, Minist Educ Beijing, Beijing, Peoples R China 4.Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Resp & Crit Care Med, Beijing 100730, Peoples R China 5.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Med Oncol, Hangzhou, Peoples R China 6.Zhejiang Univ, Affiliated Hosp 2, Dept Radiat Oncol, Sch Med, Hangzhou, Peoples R China 7.Shanghai Jiao Tong Univ, Renji Hosp, Dept Oncol, Sch Med, Shanghai, Peoples R China 8.Zhuji Peoples Hosp, Dept Resp Med & Crit Care Med, Zhuji, Zhejiang, Peoples R China 9.Zhejiang Univ, Affiliated Zhejiang Hosp, Dept Resp Med, Sch Med, Hangzhou, Zhejiang, Peoples R China 10.Zhejiang Prov Peoples Hosp, Dept Resp Med, Hangzhou, Zhejiang, Peoples R China
推荐引用方式 GB/T 7714	Shi, Yuequan,Fang, Jian,Zhou, Chengzhi,et al. Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China[J]. THORACIC CANCER,2021.
APA	Shi, Yuequan.,Fang, Jian.,Zhou, Chengzhi.,Liu, Anwen.,Wang, Yan.,...&Wang, Mengzhao.(2021).Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China.THORACIC CANCER.
MLA	Shi, Yuequan,et al."Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China".THORACIC CANCER (2021).